Vidya Gopalakrishnan, Ph.D.
Department of Pediatrics, Division of Pediatrics
About Dr. Vidya Gopalakrishnan
Medulloblastoma is a highly malignant pediatric brain tumor that is postulated to arise from the undifferentiated stem/progenitor cells of the external granule layer of the developing cerebellum. A number of studies have linked medulloblastoma genesis to aberrations in normal cerebellar development.
Read More
The overall goal of our research is to understand the role of the RE1 Silencing Transcription Factor (REST), a negative regulator of neuronal differentiation, in cerebellar development and in medulloblastoma pathogenesis. Our earlier work demonstrated that aberrant maintenance of REST expression in human medulloblastoma cell lines and immortalized cerebellar progenitors maintained proliferation, blocked neuronal specification and promoted tumor formation in the murine cerebellum. Countering REST activity in these cells induced neurogenesis and abrogated their tumorigenic potential in vivo, suggesting an important role for REST in tumor genesis.
Ongoing research in our laboratory is focused on understanding the mechanism(s) by which REST is regulated during normal neurogenesis of cerebellar stem/progenitor cells and if aberrations in these regulatory mechanisms contribute to medulloblastoma genesis. We are also interested in identifying downstream effectors of REST that may contribute to neoplasia in cerebellar stem/progenitor cells. In the long-term, these studies are expected to identify novel targets for medulloblastoma therapy.
Additional links:
Center for Cancer Epigenetics: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/programs-centers-institutes/center-for-cancer-epigenetics/index.html
UT Graduate School website: http://gsbs.uth.tmc.edu/tutorial/gopalakrishnan_v.html
PubMed publication list: http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/12GE65p075iG7oOGayl15pbAU/
Present Title & Affiliation
Primary Appointment
Associate Professor (with tenure), Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor (with tenure), Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor (with tenure), Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor (with tenure), Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US, Microbiology, Ph.D |
| 1988 | University of Bombay, Bombay, IN, Biochemistry, M.S |
| 1986 | University of Bombay, Bombay, IN, Microbiology and Biochemistry, BS |
Postgraduate Training
| 1995-2001 | Post-Doctoral Fellowship, Molecular Genetics/Biochemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2012
Assistant Professor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2012
Instructor, Department of Molecular Genetics The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2005
Instructor, Department of Biology Tomball College (Teaching Position), Tomball, TX, 2001 - 2003
Administrative Appointments/Responsibilities
Caroline Ross Brain Tumor Distinguished Lecture Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Faculty Mid-tenure Review Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Research Co-Leader-Imaging Team, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Research Co-Leader-Neural Cancers Team, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Research Co-Leader-Biospecimen Science Team, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Genetics and Epigenetics Program, Community Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2018
Coordinator-G&E Community Committee, Department of Genetics and Epigenetics, MD Anderson UT Health Graduate School, Houston, TX, 2017 - 2018
Coordinator-Pediatrics Research Seminar Series, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2018
Other Professional Positions
Internal Advisory Board, NIH Brain Tumor SPORE grant, University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
MD Anderson Cancer Neuroscience Symposium 2026 Steering Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Member, Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Faculty Senate Sub-committee on Research Integrity Officer Recruitment, University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Employee Wellness Task Force, University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Faculty Senate Sub-committee on Promotion and Tenure, University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, Faculty Senate, Sub-committee on Promotion and Tenure, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Research Laboratory Start-up Assessment, University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Member, MD Anderson UT Health Graduate School-Program in Genetics and Epigenetics, Houston, TX, 2017 - Present
Member, The University of Texas MD Anderson Cancer Center-Center for Cancer Genetics, Houston, TX, 2015 - Present
Member, MD Anderson UT Health Graduate School-Program in Clinical and Translational Sciences, Houston, TX, 2014 - Present
Member, MD Anderson UT Health Graduate School-Curriculum Committee, Houston, TX, 2013 - 2016
Leader, The University of Texas MD Anderson Cancer Center-Division of Pediatrics-Neuroimmunotherapy Research and Clinical Trials Team, Houston, TX, 2013 - Present
Institutional Research Grant (IRG) Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Member, The University of Texas MD Anderson Cancer Center-Postdoctoral Advisory Committee, Houston, TX, 2012 - 2015
Member, The University of Texas MD Anderson Cancer Center-Center for Stem Cell and Developmental Biology, Houston, TX, 2008 - 2013
Member, MD Anderson UT Health Graduate School-Program in Neuroscience-Admissions Committee, Houston, TX, 2008 - 2010
Member, MD Anderson UT Health Graduate School-Program in Neuroscience, Houston, TX, 2008 - 2017
Member, The University of Texas MD Anderson Cancer Center-Pediatric Neuro-onc Faculty Search Committee, Houston, TX, 2007 - Present
Member, The University of Texas MD Anderson Cancer Center-Center for Cancer Epigenetics, Houston, TX, 2007 - Present
Graduate Faculty, MD Anderson UT Health Graduate School, Houston, TX, 2006 - Present
Member, The University of Texas MD Anderson Cancer Center-Brain Tumor Center, Houston, TX, 2003 - Present
Intramural Institutional Committee Activities
Member, OncoPitch Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Institutional Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Institutional Research Laboratory Start-up Assessment, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Member, Institutional Chair Search Committee - Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, Institutional Chair Search Committee - Interventional Radiology, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Extramural Institutional Committee Activities
Member, Institutional Research Grant Committee-Basic Research, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Multidisciplinary Research Advisory Committee (MRAC), The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Institutional Research Grant Committee-Basic Research, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Editorial Activities
Associate Editor, Frontiers in Oncology, 2019 - Present
Editorial Board, Scientific Reports, 2019 - Present
Editorial Board, Frontiers in Biological-Chemistry, 2014 - 2021
Honors & Awards
| 2025 - Present | Invited Speaker, GBMRO Annual Summit, Miami Florida |
| 2024 - Present | Invited Speaker, GBMRO Inaugural Summit, Miami, Florida |
| 2019 - Present | President’s Award for Scientific Excellence, The University of Texas MD Anderson Cancer Center |
| 2017 - 2024 | Nominee, Mid-Career Women Faculty Leadership Development Program |
| 2016 - 2017 | Member, Faculty Leadership Academy MD Anderson Cancer Center |
| 2016 | Nominee, Regent's Outstanding Teaching Award |
| 2016 | Nominee, Robert M. Chamberlain Distinguished Mentor Award-Finalist |
| 2015 | Finalist, Robert M. Chamberlain Distinguished Mentor Award |
| 2013 | Invited Speaker, Noah’s Light Foundation Disney Princess Rally, Orlando, FL |
| 2012 | Invited Speaker, American Cancer Society Cattle Barron's Fund Raising Event |
| 2012 | Invited Speaker, American Cancer Society Laureate Society Fund Raising Event, Miami, Fl |
| 2012 | Invited Speaker, American Cancer Society Rally for Life Summit, Dallas, TX |
| 2011 - 2024 | Medical Advisory Board, Rally Foundation for Pediatric Cancers, Atlanta, GA |
| 1997 - 2000 | Fellow, Leukemia and Lymphoma Society of America |
| 1997 - 2000 | Fellow, Ruth L. Kirschstein National Research Service Award (NRSA)/NIH (Relinquished due to overlap with Leukemia and Lymphoma Society grant) |
| 1989 - 1990 | Fellow, Ben Franklin Biotechnology Training Program, Pittsburgh, PA |
| 1988 - 1999 | Scholar, J. N. Tata Endowment, India |
| 1988 - 1989 | Fellow, Dean's List-University of Pittsburgh, School of Medicine |
| 1983 - 1988 | Scholar, State of Maharashtra Government, India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Preclinical MPI imaging of NK cells. Invited. Houston, Texas, US.
- 2023. Deconstructing REST function in Medulloblastoma. Invited. Houston, Texas, US.
- 2020. REST and regulation of medulloblastoma vasculature. Brain tumor Center Chalk Talk Series. Houston, Texas, US.
- 2020. Alternative exon usage in medulloblastoma. Invited. Research Exchange Seminar. Houston, Texas, US.
- 2018. Bench to bedside, Update in pediatric neuro-oncology. Institutional Grand Rounds. Houston, Texas, US.
- 2017. REST promotes medulloblastoma metastasis. Conference. REST promotes medulloblastoma metastasis. Houston, TX, US.
- 2015. Epigenetics in pediatric brain tumors. Conference. Epigenetics in pediatric brain tumors. Houston, TX, US.
- 2015. Chromatin modifiers in pediatric brain tumors: From mechanisms to therapy. Conference. Chromatin modifiers in pediatric brain tumors: From mechanisms to therapy. Houston, TX, US.
- 2014. Epigenetics in the cross-hairs of medulloblastoma development. Conference. Epigenetics in the cross-hairs of medulloblastoma development. Houston, TX, US.
- 2014. NK cell immunotherapy for Pediatrics brain tumors. Conference. NK cell immunotherapy for Pediatrics brain tumors. Houston, TX, US.
- 2013. Updates in pediatric brain tumors. Conference. Updates in pediatric brain tumors. Houston, TX, US.
- 2010. Targeted therapies for brain tumors. Conference. Targeted therapies for brain tumors. Houston, TX, US.
- 2008. Epigenetics of neuronal differentiation and brain tumor therapy. Conference. Epigenetics of neuronal differentiation and brain tumor therapy. Houston, TX, US.
- 2006. REST and cancer: is too much of a good thing bad?. Conference. REST and cancer: is too much of a good thing bad?. Houston, TX, US.
- 2005. Role of REST in medulloblastoma tumorigenesis. Conference. Role of REST in medulloblastoma tumorigenesis. Houston, TX, US.
National Presentations
- 2025. Update on Research and Therapeutics Discovery for Childhood Cancers. Invited. GBMRO Annual Symposium, US.
- 2025. Isoform Switch in Medulloblastoma Metastasis. Invited. Cold Spring Harbor Conference on Advances in Brain Tumors. Cold Spring Harbor, New York, US.
- 2024. Epigenetic reprogramming of pediatric brain tumors in immune evasion. Invited. Philadelphia, PA, US.
- 2024. Update on research and therapeutics discovery for childhood brain cancers. Invited. Miami, FL, US.
- 2024. Cold Spring Harbor Laboratories-Course on Brain Tumors. Invited. Long Island, NY, US.
- 2023. Basic Mechanisms to Clinical Trials in Brain Tumors. Invited. Bryant, RI, US.
- 2022. Carson Leslie Childhood Cancer Symposium. Invited. Dallas, TX, US.
- 2022. Monitoring the fate of cellular therapy using biological reporters. Invited. Atlanta, GA, US.
- 2020. Cellular stress response in DIPG therapy (student talk). Invited. Austin, TX, US.
- 2018. Investigating the role of neurogenic regulator REST in cerebellar development and medulloblastoma dissemination. Conference. Investigating the role of neurogenic regulator REST in cerebellar development and medulloblastoma dissemination. Keystone, CO, US.
- 2017. Illuminating the role of neurogenic regulator REST in medulloblastoma dissemination. Conference. Illuminating the role of neurogenic regulator REST in medulloblastoma dissemination. Philadelphia, PA, US.
- 2015. Pilot clinical trial evaluating chemotherapy administration directly into the fourth ventricle in children with malignant fourth ventricular tumors. Conference. Pilot clinical trial evaluating chemotherapy administration directly into the fourth ventricle in children with malignant fourth ventricular tumors. Seattle, WA, US.
- 2013. Noah's Light Foundation Disney Princess Rally. Invited. Orlando, FL, US.
- 2013. Identification of USP37 as a novel tumor suppressor in medulloblastoma. Conference. Identification of USP37 as a novel tumor suppressor in medulloblastoma. Ft. Lauderdale, FL, US.
- 2013. Epigenetic modulation of the novel tumor suppressor USP37 in medulloblastoma. Conference. Epigenetic modulation of the novel tumor suppressor USP37 in medulloblastoma. Boston, MA, US.
- 2013. Targeting histone methylation for ATRT therapy. Conference. Targeting histone methylation for ATRT therapy. Boston, MA, US.
- 2013. Natural killer cell for therapy of neural tumors. Conference. Natural killer cell for therapy of neural tumors. Boston, MA, US.
- 2012. American Cancer Society Cattle Barron's Fund-Raising Event. Invited, US.
- 2012. American Cancer Society Rally for Life Summit. Invited. Dallas, TX, US.
- 2012. American Cancer Society Laureate Society Fund Raising Event. Invited. Miami, FL, US.
- 2012. Natural killer cell for therapy of neural tumors. Conference. Natural killer cell for therapy of neural tumors, PA, US.
- 2008. Valproic acid synergizes with etoposide in medulloblatoma: p53-dependent and p53-independent mechanisms. Conference. Valproic acid synergizes with etoposide in medulloblatoma: p53-dependent and p53-independent mechanisms. San Diego, CA, US.
- 2006. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron restrictive silencing factor, which can be functionally countered by REST-VP16. Conference. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron restrictive silencing factor, which can be functionally countered by REST-VP16. Napa Valley, CA, US.
- 2001. Interaction of Cdt1 and Cdc18 in the control of S. pombe DNA replication. Conference. Interaction of Cdt1 and Cdc18 in the control of S. pombe DNA replication. Cold Spring Harbor, NY, US.
- 2000. The role of fission yeast protein Cdt1 in the initiation of DNA replication. Conference. The role of fission yeast protein Cdt1 in the initiation of DNA replication. Cold Spring Harbor, NY, US.
- 1999. "Use of hybrid proteins to identify the "Replication Specificty" and E2 interaction domains of the HPV E1 proteins". Conference. "Use of hybrid proteins to identify the "Replication Specificty" and E2 interaction domains of the HPV E1 proteins". Cold Spring Harbor, NY, US.
- 1997. Role and specificity of E1 protein in human papillomavirus replication. Conference. Role and specificity of E1 protein in human papillomavirus replication. Cold Spring Harbor, NY, US.
- 1995. Role of E1 and E2 proteins in human papillomavirus replication. Conference. Role of E1 and E2 proteins in human papillomavirus replication. Cold Spring Harbor, NY, US.
- RNA processing and epigenetic regulation in pediatric brain cancers. Invited. Advances to Brain Tumor Research and Therapy. Cold Spring Harbor, New York, US.
International Presentations
- 2024. Preclinical and clinical-scale magnetic particle imaging of Natural Killer cells: in vitro and ex vivo demonstration of cellular sensitivity, resolution, and quantification. Quebec, CA.
- 2018. Long range chromatin interactions control response of ATRT to immunotherapy. Conference. Long range chromatin interactions control response of ATRT to immunotherapy. Banff, CA.
- 2015. A novel genetically engineered mouse model of medulloblastoma informs on brain tumor metastasi. Conference. A novel genetically engineered mouse model of medulloblastoma informs on brain tumor metastasi. Kochi, IN.
- 2015. Immunotherapy for pediatric brain tumors. Conference. Immunotherapy for pediatric brain tumors. Kochi, IN.
- 2015. In vivo 19F MRI of labeled natural killer cells 19F imaging to monitor delivery of immune cells in the brain. Conference. In vivo 19F MRI of labeled natural killer cells 19F imaging to monitor delivery of immune cells in the brain. San Diego, US.
- 2015. A novel genetically engineered mouse model of medulloblastoma informs on brain tumor metastasis. Conference. A novel genetically engineered mouse model of medulloblastoma informs on brain tumor metastasis. Kochi, IN.
- 2014. Generation of a novel mouse model of medulloblastoma. Conference. Generation of a novel mouse model of medulloblastoma, SG.
- 2014. A novel mouse informs on medulloblastoma initiation. Conference. A novel mouse informs on medulloblastoma initiation. Lucknow, IN.
- 2013. Identification of a novel tumor suppressive deubiquitylase in medulloblastoma. Conference. Identification of a novel tumor suppressive deubiquitylase in medulloblastoma. Amsterdam, NL.
- 2013. REST a poor prognostic factor in medulloblastoma is targeted for proteasmal degradation by HDAC inhibitors. Conference. REST a poor prognostic factor in medulloblastoma is targeted for proteasmal degradation by HDAC inhibitors. Dubai, AE.
- 2012. Natural killer cell for therapy of neural tumors. Conference. Natural killer cell for therapy of neural tumors. Frankfurt, DE.
- 2012. Natural killer cell for therapy of neural tumors. Conference. Natural killer cell for therapy of neural tumors. San Paulo, BR.
- 2011. Novel role for REST in the control of cell proliferation in medulloblastoma. Conference. Novel role for REST in the control of cell proliferation in medulloblastoma. Philadelphia, US.
- 2011. Modulation of REST activity directs glutamatergic differentiation of myoblasts in the murine cerebellum. Conference. Modulation of REST activity directs glutamatergic differentiation of myoblasts in the murine cerebellum. Beijing, CN.
- 2011. Modulating neuronal specification in pediatrics brain tumors. Conference. Modulating neuronal specification in pediatrics brain tumors. Udaipur, IN.
- 2011. Targeting REST activity promotes glutamatergic fifferentiation of myoblasts in the murine cerebellum. Conference. Targeting REST activity promotes glutamatergic fifferentiation of myoblasts in the murine cerebellum. Philadelphia, US.
- 1999. Role of the E1 and E2 proteins in human papillomavirus replication and its regulation. Conference. Role of the E1 and E2 proteins in human papillomavirus replication and its regulation. Cambridge, GB.
- 1995. Role of human papillomavirus type 1a E1 and E2 proteins in the initiation of viral DNA replication. Conference. Role of human papillomavirus type 1a E1 and E2 proteins in the initiation of viral DNA replication. Quebec City, CA.
- 1994. Role of human papillomavirus type 1a E1 and E2 proteins in the initiation of viral DNA replication. Conference. Role of human papillomavirus type 1a E1 and E2 proteins in the initiation of viral DNA replication. New Delhi, IN.
- 1994. Role of transcription factor E2 in the initiation of human papillomavirus DNA replication. Conference. Role of transcription factor E2 in the initiation of human papillomavirus DNA replication. Bangalore, IN.
Formal Peers
- 2018. Epigenetics meets immunology in pediatric brain tumors. Invited. Charlottsville, VA, US.
- 2017. Epigenetics in medulloblastoma progression: Opportunity for therapeutics development. Invited. Houston, TX, US.
- 2016. Epigenetics in medulloblastoma progressio: Opportunity for therapeutics development. Invited. Columbus, OH, US.
- 2016. Targeting the medulloblastoma for cancer therapy. Invited. Salerno, IT.
- 2016. Deregulation of the medulloblastoma epigenome drives leptomeningeal dissemination in a novel genetically mouse model. Invited. San Antonio, TX, US.
- 2016. Epigenetic cooperativity in Shh-driven medulloblastoma. Invited. Dallas, TX, US.
- 2016. Drivers of leptomeningeal dissemination of medulloblastoma: applying biology to therapeutics discovery. Invited. Atlanta, GA, US.
- 2015. Chromatin remodelers in pediatric brain tumors. Invited. College Station, TX, US.
- 2014. Epigenetics in medulloblastoma development. Invited. Bangalore, IN.
- 2014. Epigenetics in medulloblastoma theraphy. Invited. Vellore, IN.
- 2014. Medulloblatoma epigenetics guides therapeutics development. Invited. Toronto, CA.
- 2014. Chromatin modifiers in pediatric brain tumors: From mechanisms to therapy. Invited. Pittsburgh, PA, US.
- 2013. Epigenetic deregulation of a novel deubiquitylase in medulloblastoma genesis. Invited, IN.
- 2013. NK Immunotherapy for pediatric brain tumors. Invited, IN.
- 2012. REST in medulloblatoma and neuronal lineage specification. Invited. Atlanta, GA, US.
- 2012. Mechanisms of REST-mediated tumorigenesis. Invited. Chicago, IL, US.
- 2011. Molecular Mechanisms of REST-mediated medulloblastoma genesis. Invited. Providence, RI, US.
- 2011. REST in brain cancer and neuroregeneration. Invited. Istanbul, TR.
- 2008. REST and the RESTless: implications for cancer and cellular plasticity. Invited. Dayton, OH, US.
- 2008. REST: roles in brain development and cancer. Invited. Chicago, IL, US.
- 2008. REST: roles in brain development and cancer. Invited. Fort Worth, TX, US.
- 2007. VPA synergizes with etoposide in brain tumor cells. Invited. New Delhi, IN.
- 2006. REST in cancer: potential for targeted therapy. Invited. Potsdam, NY, US.
- 2006. REST in Cancer: potential for targeted therapy. Invited. West Lafayette, IN, US.
- 2005. Role of REST in medulloblastoma tumorigenesis. Invited. Columbus, OH, US.
- 2005. REST a novel mediator of medulloblastoma tumorigenesis. Invited. Mumbai, IN.
- 2002. Cell cycle regulation of DNA replication in the fission yeast S. Pombe. Invited. Ann Arbor, MI, US.
- 1995. Role of HPV E1 protein in viral DNA replication. Invited. Baltimore, MD, US.
- 1994. Human papillomavirus DNA replication. Invited. Ann Arbor, MI, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Magnetic Particle Imaging for Advanced Cellular Therapy Tracking"(MAG-PACT)” |
| Funding Source: | NIH |
| Role: | Co-PI |
| Date: | 2026 - 2031 |
| Title: | Cilia as a genetic dependency in SHH medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2026 - Present |
| Title: | Isoform switch in disseminated SHH-driven Medublastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2026 - 2028 |
| Title: | Study of VHL tumor suppressor in medulloblastoma |
| Funding Source: | American Cancer Society Fellowship |
| Role: | Mentor |
| Date: | 2026 - 2031 |
| Title: | Study of primary cilium maintenance as a dependency in SHH medulloblastoma |
| Funding Source: | NIH |
| Role: | Co-PI |
| Date: | 2026 - 2030 |
| Title: | Study of primary cilium maintenance as a dependency in SHH medulloblastoma |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | Co-PI |
| ID: | RP260032 |
| Date: | 2026 - 2027 |
| Title: | Cell-cell communication axis for therapeutics and biomarker development |
| Funding Source: | Rally Foundation for Childhood Cancers |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Following adoptively transferred NK cells for Osteosarcoma |
| Funding Source: | University of Maryland - Baltimore |
| Role: | PI |
| Date: | 2026 - 2030 |
| Title: | Leveraging inhibition of LSD1/KDM1A to augment immunotherapy of pediatric high grade glioma |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | Co-PI |
| Date: | 2026 - 2030 |
| Title: | Cilia as a genetic dependency in SHH medulloblastoma |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Date: | 2026 - 2026 |
| Title: | USP37 at the cross roads of cancer and neurodegeneration |
| Funding Source: | O'Quinn Foundation |
| Role: | PI |
| Date: | 2025 - 2027 |
| Title: | Converting "cold" to "hot": Improving medulloblastoma sensitivity to NK cell immunotherapy |
| Funding Source: | Team Jack Foundation |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Repurposing Migraine Treatments for DIPG |
| Funding Source: | Uncle Kory Foundation |
| Role: | PI |
| ID: | FP00025466 |
| Date: | 2025 - 2030 |
| Title: | REST-SOX2 interaction in medulloblastoma for therapeutics and biomarker discovery |
| Funding Source: | NIH |
| Role: | PI |
| ID: | GRANT14347635 |
| Date: | 2025 - 2030 |
| Title: | Deubiquitylase USP37 in Hedgehog-driven medulloblastoma |
| Funding Source: | NIH/NINDS/NCI |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | Studying adoptive transfer of NK and CAR-NK cells against OS, either alone or in combination to improve efficacy, trafficking and persistence |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Targeting autophagy for NK cell therapy |
| Funding Source: | Uncle Kory Foundation |
| Role: | Co-PI |
| Date: | 2025 - 2029 |
| Title: | Convergent Science Cancer Consortium For Immune Cell Engineering |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | CA240991 |
| Date: | 2025 - 2027 |
| Title: | Antigen discovery of TCR targets for pediatric glioma |
| Funding Source: | Lindon Light Collective |
| Role: | Co-PI |
| Date: | 2025 - 2030 |
| Title: | Equipment: Development of a Preclinical Magnetic Particle Imaging System Tailored for Cancer Cell Therapy |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Co-I |
| ID: | 2509874 |
| Date: | 2025 - 2030 |
| Title: | Childhood and Adolescent/Young Adult Cancer Research Resource (CARE) |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP250546 |
| Date: | 2025 - 2030 |
| Title: | REST-driven MB cellular heterogeneity in therapeutics and biomarker development |
| Funding Source: | NIH |
| Role: | PI |
| ID: | NS142234 |
| Date: | 2025 - 2029 |
| Title: | Neurovascular uncoupling and mitigation in pediatric high-grade gliomas |
| Funding Source: | UT Austin and UT MD Anderson Cancer Center Strategic Collaboration |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Anti-depressants for DIPG therapy |
| Funding Source: | McGary Regan Foundation |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Pre-Clinical Research of Diffuse Intrinsic Pontine Glioma |
| Funding Source: | The University of Texas Foundation |
| Role: | PI |
| Date: | 2024 - 2028 |
| Title: | Study of a REST-context specific therapeutic vulnerability in DIPG |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Targeting REST regulome in medulloblastomas to enhance NK cell immunotherapy |
| Funding Source: | CURE Childhood Cancer |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | New approach for osteosarcoma: Enhancing and monitoring NK cell therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | REST-regulated postnatal cerebellar inter-cellular dynamics |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Priming preclinical magnetic particle Imaging (MPI) for brain Tumor NK Cell tracking in Humans (PITCH) |
| Funding Source: | NIBIB-AIP |
| Role: | Co-I |
| Date: | 2022 - 2026 |
| Title: | HDO Imaging is a Quantitative Marker of Cerebral Glucose Oxidation |
| Funding Source: | NIH |
| Role: | Consult |
| ID: | EB032376 |
| Date: | 2022 - 2027 |
| Title: | Alternative transcript synthesis in medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2022 - 2027 |
| Title: | Heterozygous KMT2D loss in medulloblastoma |
| Funding Source: | NIH |
| Role: | Key |
| ID: | CA262324 |
| Date: | 2021 - 2022 |
| Title: | Repositioning Therapeutics for DIPG |
| Funding Source: | B*Cured |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | ONC201 as an immunosensitizer for DIPGs |
| Funding Source: | Chance for Hope Foundation |
| Role: | Co-PI |
| Date: | 2021 - 2026 |
| Title: | Study of PRC2-independent mechanisms in DIPG |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Repurposing migraine treatment for DIPG |
| Funding Source: | Uncle Kory Foundation |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Study of ONC201 as an immunosensitizer for DIPGs |
| Funding Source: | Chance for Hope Foundation |
| Role: | Mentor |
| Date: | 2019 - 2023 |
| Title: | NK Cell Therapy for Refractory or Relapsed Osteosarcoma |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2018 - 2024 |
| Title: | Pediatric Solid Tumors Comprehensive Data Resource Core |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP180819 |
| Date: | 2018 - 2020 |
| Title: | Advancing19F MRI NK cell tracking probes using amphiphilic peptide platform |
| Funding Source: | NIH/NIBIB |
| Role: | Co-I |
| Date: | 2018 - 2022 |
| Title: | Youth enjoy science Education Program |
| Funding Source: | NIH/NCI |
| Role: | Significant Contributor |
| Date: | 2018 - 2023 |
| Title: | Study of a novel deubiquitylase in medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| Date: | 2017 - 2021 |
| Title: | Developing NK cell immunotherapy for medulloblastoma and fourth ventricular tumors |
| Funding Source: | Stripes and Sunoco |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Role of histone methyl transferase MLL4 in medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | Significant Contributor |
| ID: | 1R01CA20710901A1 |
| Date: | 2017 - 2022 |
| Title: | EWS-FLI1 and REST regulate tumor vascular pericytes in Ewing's Sarcoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2025 |
| Title: | A screen for epigenetics vulnerabilities in DIPG |
| Funding Source: | Ann Parsons Memorial Foundation |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Development of novel imaging modalities to monitor immune cells infused loco-regionally for brain tumor therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Project Leader |
| Date: | 2015 - 2017 |
| Title: | Targeting LSD1 in novel combinations for medulloblastoma therapy |
| Funding Source: | NIH Center for Clinical and Translational Sciences (CCTS)-TL1 training program |
| Role: | Mentor |
| Date: | 2015 - 2017 |
| Title: | Targeting immune evasion in atypical teratoid rhabdoid tumors |
| Funding Source: | Rally Foundation for Childhood Cancer Research and Bear Necessities Foundation |
| Role: | Mentor |
| Date: | 2015 - 2018 |
| Title: | Phase-I Immunotherapy clinical trial for recurrent pediatric brain tumors |
| Funding Source: | Rally Foundation for Childhood Cancer Research |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Phase-I trial to study the safety and feasibility of infusing autologous ex vivo expanded NK cells in children with fourth ventricular tumors |
| Funding Source: | Rally Vs Cancer Foundation for Childhood Cancer Research |
| Role: | PI |
| Date: | 2015 - 2020 |
| Title: | Epigenetics in medulloblastoma development and therapeutics |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Immunotherapy for pediatric brain tumors |
| Funding Source: | UT MD Anderson Cancer Center-Glioblastoma Moonshot |
| Role: | Co-PI |
| Date: | 2014 - 2015 |
| Title: | Phase-I trial to study the safety and feasibility of infusing autologous ex vivo expanded NK cells in children with fourth ventricular tumors |
| Funding Source: | Dr. Marnie Rose Foundation |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Targeting selectins in Neuroblastoma |
| Funding Source: | Emily Power |
| Role: | PI |
| Date: | 2014 - 2018 |
| Title: | Phase I Study of fourth ventricle infusions of autologous ex vivo-expanded NK cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system |
| Funding Source: | Solving Kids’ Cancer (SKC) |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Role of REST in medulloblastoma genesis |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | 118165-RSG-09-273-01-DDC-Supplement |
| Date: | 2014 - 2015 |
| Title: | Harnessing the immune system to target diffuse intrinsic pontine glioma (DIPG) |
| Funding Source: | The Cure Starts Now |
| Role: | Co-PI |
| Date: | 2013 - 2014 |
| Title: | Epigenetic basis of leptomeningeal disease in medulloblastoma |
| Funding Source: | Center for Cancer Epigenetics (CCE) |
| Role: | Mentor |
| Date: | 2013 - 2015 |
| Title: | Targeting REST activity in medulloblastoma |
| Funding Source: | Rally Vs Cancer Foundation for Childhood Cancer Research |
| Role: | PI |
| Date: | 2013 - 2017 |
| Title: | Developing NK cell immunotherapy for medulloblastoma and fourth |
| Funding Source: | Noah’s Light Foundation |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Pre-Clinical testing of T cells coded with EGFR-specific CAR for DIPG |
| Funding Source: | Alex's Lemonade Stand Foundation |
| Role: | Collaborator |
| Date: | 2012 - 2015 |
| Title: | Applied natural killer cell immunotherapy for medulloblastoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | Pediatric diffuse intrinsic pontine gliomas (DIPG): Evaluation of tumor biology utilizing patient tumor samples and development of a genetically engineered mouse model |
| Funding Source: | Hyundai Hope on Wheels Scholar Grant |
| Role: | Co-I |
| Date: | 2012 - 2015 |
| Title: | Study of REST in cerebellar development and medulloblastoma |
| Funding Source: | National Brain Tumor Society |
| Role: | PI |
| Date: | 2012 - 2018 |
| Title: | Study of a novel deubiquitylase in medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 5R01NS079715 |
| Date: | 2012 - 2018 |
| Title: | Pre-clinical and clinical studies of REST in medulloblastoma |
| Funding Source: | Rally Foundation for Childhood Cancer Research |
| Role: | PI |
| Date: | 2011 - 2013 |
| Title: | Development of novel mouse models to study REST function in medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 1 R03 NS077021-01 |
| Date: | 2011 - 2016 |
| Title: | Preclinical and clinical study targeting REST for medulloblastoma therapy |
| Funding Source: | St. Baldrick's Foundation |
| Role: | PI |
| Date: | 2011 - 2016 |
| Title: | Translational Research Training for Pediatric Hematology/Oncology Fellows |
| Funding Source: | Ruth L. Kirschstein National Research Service Award (NRSA)Institutional Research Training Grants (T32) |
| Role: | Co-I |
| ID: | PA-10-036 |
| Date: | 2011 - 2028 |
| Title: | Study of histone methyl transferases in atypical teratoid rhabdoid tumor (ATRT) |
| Funding Source: | Addis Faith Foundation |
| Role: | PI |
| Date: | 2010 - 2015 |
| Title: | REST and regulation of proliferation in cerebellar progenitors and medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 1R01NS072384-01 |
| Date: | 2010 - 2011 |
| Title: | Study of RE1 Silencing Transcription Factor (REST) as a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma |
| Funding Source: | Matthew Larson Pediatric Brain Tumor Foundation |
| Role: | Co-PI |
| Date: | 2010 - 2013 |
| Title: | REST in medulloblastoma |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | PR093179 |
| Date: | 2009 - 2012 |
| Title: | Neural stem cells for gene delivery in brain tumors |
| Funding Source: | Alliance for Cancer Gene Therapy |
| Role: | PI |
| ID: | 123089 |
| Date: | 2008 - 2013 |
| Title: | Study of REST biology in medulloblastoma |
| Funding Source: | NIH/NCI/NINDS |
| Role: | PI |
| ID: | R01CA138518-01 |
| Date: | 2008 - 2010 |
| Title: | Career Development Program (CDP) |
| Funding Source: | "SPORE in Brain Cancer" |
| Role: | Investigator |
| ID: | P50CA127001 |
| Date: | 2008 - 2010 |
| Title: | Medulloblastoma: On the TRAIL to Apoptosis |
| Funding Source: | UTMDACC ACS-IRG Pilot Project Award |
| Role: | PI |
| ID: | IRG-08-061-01 |
| Date: | 2007 - 2009 |
| Title: | Modulators of Apoptosis for Medulloblastoma Therapy |
| Funding Source: | National Brain Tumor Foundation |
| Role: | PI |
| Date: | 2006 - 2007 |
| Title: | Study of HDAC Inhibitors as Adjuvants to Etoposide in Medulloblastoma Treatment |
| Funding Source: | Texas Federation of Business & Professional Women |
| Role: | PI |
| Date: | 2004 - 2007 |
| Title: | Role of REST/NRSF in Medulloblastoma Tumorigenesis |
| Funding Source: | Children's Brain Tumor Foundation |
| Role: | PI |
| Date: | 2004 - 2007 |
| Title: | Role of REST/NRSF in medulloblatoma |
| Funding Source: | Pediatric Brain Tumor Foundation (relinquished due to overlap) |
| Role: | PI |
| Date: | 2004 - 2007 |
| Title: | Role of Cdt1 in regulation of DNA replication and G1/S transitionin fission yeast |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2004 - 2006 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | MDACC Internal Research Grant (relinquished due to overlap) |
| Role: | Principal Investigator-MDACC |
| Date: | 1997 - 2000 |
| Title: | Role of Cdt1 in regulation of DNA replication and G1/S transitionin fission yeast |
| Funding Source: | Post-Doctoal fellowship Ruth L. Kirschstein National Research Service Award |
| Role: | PI |
| Date: | 1997 - 2000 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | NIH/NRSA Ruth L. Kirschstein |
| Role: | PI |
| Date: | 1989 - 1990 |
| Title: | Study of human papilloma virus DNA replication |
| Funding Source: | Ben Franklin Biotechnology Training Program Graduate Fellowship |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Mahendran MIMS, Gopalakrishnan V, Saravanan V, Vaithianathan R. Necrotising fasciitis post-trauma. BMJ Case Rep 18(2), 2025. e-Pub 2025. PMID: 39956560.
- Gopalakrishnan V, Sparklin B, Kim JH, Bouquet J, Kehl M, Kenny T, Morehouse C, Caceres C, Warrener P, Hristova VA, Wilson S, Shandilya H, Barnes A, Ruzin A, Wang J, Oberg L, Angermann B, McCrae C, Platt A, Muthas D, Hess S, Tkaczyk C, Sellman BR, Ostridge K, Belvisi MG, Wilkinson TMA, Staples KJ, DiGiandomenico A. NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome. Respir Res 26(1):45, 2025. e-Pub 2025. PMID: 39885466.
- Carrod AJ, Berghuis AM, Gopalakrishnan VN, Monkman A, Danos A, Borjesson K. Separating triplet exciton diffusion from triplet-triplet annihilation by the introduction of a mediator. Chem Sci 16(3):1293-1301, 2025. e-Pub 2025. PMID: 39677941.
- Patel RR, Gopalakrishnan V, Amini B, Lazar AJ, Lin PP, Benjamin RS, Bishop AJ, Goepfert RP, Araujo DM. Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma. Cancers (Basel) 16(23), 2024. e-Pub 2024. PMID: 39682304.
- Sehl OC, Yang Y, Anjier AR, Nevozhay D, Cheng D, Guo K, Fellows B, Mohtasebzadeh AR, Mason EE, Sanders T, Kim P, Trease D, Koul D, Goodwill PW, Sokolov K, Wintermark M, Gordon N, Greve JM, Gopalakrishnan V. Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification. Mol Imaging Biol, 2024. e-Pub 2024. PMID: 39653984.
- Arbetter D, Gopalakrishnan V, Aksyuk AA, Ahani B, Chang Y, Dagan R, Esser MT, Hammitt LL, Mankad VS, Saez-Llorens X, Shen D, Leach A, Kelly EJ, Villafana T, Wilkins D. Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY). Clin Infect Dis, 2024. e-Pub 2024. PMID: 39656748.
- Gopalakrishnan V, Saravanan V, Mahendran MIMS, Kumar MPN. Helicobacter pylori biofilm interference by N-acyl homoserine lactonases: in vitro and in silico approaches. Mol Biol Rep 51(1):1106, 2024. e-Pub 2024. PMID: 39476276.
- Samayamuthu MJ, Kravchenko O, Lo-Ciganic WH, Sadhu EM, Yang S, Visweswaran S, Gopalakrishnan V. Trends in Postpartum Hemorrhage Prevalence and Comorbidity Burden: Insights from the ENACT Network Aggregated Electronic Health Record Data. Res Sq, 2024. e-Pub 2024. PMID: 39399687.
- Gopalakrishnan V, Saxena P, Thakur P, Lipatov A, Sani RK. Impact of Graphene Layers on Genetic Expression and Regulation within Sulfate-Reducing Biofilms. Microorganisms 12(9), 2024. e-Pub 2024. PMID: 39338434.
- Thakur P, Gopalakrishnan V, Saxena P, Subramaniam M, Goh KM, Peyton B, Fields M, Sani RK. Influence of Copper on Oleidesulfovibrio alaskensis G20 Biofilm Formation. Microorganisms 12(9), 2024. e-Pub 2024. PMID: 39338422.
- Frisken SF, Haouchine N, Chlorogiannis DD, Gopalakrishnan V, Cafaro A, Wells WT, Golby AJ, Du R. VESCL: an open source 2D vessel contouring library. Int J Comput Assist Radiol Surg 19(8):1627-1636, 2024. e-Pub 2024. PMID: 38879659.
- Singh A, Cheng D, Swaminathan J, Yang Y, Zheng Y, Gordon N, Gopalakrishnan V. REST-dependent downregulation of von Hippel-Lindau tumor suppressor promotes autophagy in SHH-medulloblastoma. Sci Rep 14(1):13596, 2024. e-Pub 2024. PMID: 38866867.
- Truong DD, Weistuch C, Murgas KA, Admane P, King BL, Chauviere Lee J, Lamhamedi-Cherradi SE, Swaminathan J, Daw NC, Gordon N, Gopalakrishnan V, Gorlick RG, Somaiah N, Deasy JO, Mikos AG, Tannenbaum A, Ludwig J. Mapping the Single-cell Differentiation Landscape of Osteosarcoma. Clin Cancer Res 30(15):3259-3272, 2024. e-Pub 2024. PMID: 38775859.
- Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson A, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Navin NE, Gorlick R, Ludwig JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC Cancer 23(1):488, 2023. e-Pub 2023. PMID: 37254069.
- Lee J, Savage H, Maegawa S, Ballarò R, Pareek S, Guerrouahen BS, Gopalakrishnan V, Schadler K. Exercise Promotes Pro-Apoptotic Ceramide Signaling in a Mouse Melanoma Model. Cancers (Basel) 14(17), 2022. e-Pub 2022. PMID: 36077841.
- Maegawa S, Gopalakrishnan V. PLK inhibitors come of age in pediatric brain tumors. Neuro Oncol 24(3):427-428, 2022. e-Pub 2022. PMID: 35015893.
- Siddaway R, Milos S, Vadivel AKA, Dobson THW, Swaminathan J, Ryall S, Pajovic S, Patel PG, Nazarian J, Becher O, Brudno M, Ramani A, Gopalakrishnan V, Hawkins C. Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nat Commun 13(1):588, 2022. e-Pub 2022. PMID: 35102191.
- Swaminathan J, Maegawa S, Shaik S, Sharma A, Bravo-Alegria J, Guo L, Xu L, Harmanci A, Gopalakrishnan V. Cross-Talk Between Histone Methyltransferases and Demethylases Regulate REST Transcription During Neurogenesis. Front Oncol 12:855167, 2022. e-Pub 2022. PMID: 35600406.
- Shaik S, Maegawa S, Gopalakrishnan V. Medulloblastoma: novel insights into emerging therapeutic targets. Expert Opin Ther Targets 25(8):615-619, 2021. e-Pub 2021. PMID: 34602009.
- Shaik S, Maegawa S, Haltom AR, Wang F, Xiao X, Dobson T, Sharma A, Yang Y, Swaminathan J, Kundra V, Li XN, Schadler K, Harmanci A, Xu L, Gopalakrishnan V. REST promotes ETS1-dependent vascular growth in medulloblastoma. Mol Oncol 15(5):1486-1506, 2021. e-Pub 2021. PMID: 33469989.
- Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, Madakamutil L, Overwijk WW, Zalevsky J, Gordon N. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer 148(8):1928-1937, 2021. e-Pub 2021. PMID: 33152115.
- Gong S, Maegawa S, Yang Y, Gopalakrishnan V, Zheng G, Cheng D. Licochalcone A is a Natural Selective Inhibitor of Arginine Methyltransferase 6. Biochem J 478(2):389-406, 2021. e-Pub 2020. PMID: 33245113.
- Bailey CP, Figueroa M, Gangadharan A, Yang Y, Romero MM, Kennis BA, Yadavilli S, Henry V, Collier T, Monje M, Lee DA, Wang L, Nazarian J, Gopalakrishnan V, Zaky W, Becher OJ, Chandra J. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro Oncol 22(9):1302-1314, 2020. e-Pub 2020. PMID: 32166329.
- Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol 22(8):1214-1225, 2020. e-Pub 2020. PMID: 32152626.
- Harmanci A, Harmanci AS, Swaminathan J, Gopalakrishnan V. EpiSAFARI: sensitive detection of valleys in epigenetic signals for enhancing annotations of functional elements. Bioinformatics 36(4):1014-1021, 2020. e-Pub 2020. PMID: 31501853.
- Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol 142(3):409, 2019. e-Pub 2019. PMID: 30968268.
- Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol 142(3):395-407, 2019. e-Pub 2019. PMID: 30788681.
- Currier AW, Kolb EA, Gorlick RG, Roth ME, Gopalakrishnan V, Sampson VB. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. Sci Rep 9(1):6161, 2019. e-Pub 2019. PMID: 30992462.
- Dobson THW, Tao RH, Swaminathan J, Maegawa S, Shaik S, Bravo-Alegria J, Sharma A, Kennis B, Yang Y, Callegari K, Haltom AR, Taylor P, Kogiso M, Qi L, Khatua S, Goldman S, Lulla RR, Fangusaro J, MacDonald TJ, Li XN, Hawkins C, Rajaram V, Gopalakrishnan V. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Sci Signal 12(565), 2019. e-Pub 2019. PMID: 30670636.
- Callegari K, Maegawa S, Bravo-Alegria J, Gopalakrishnan V. Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration. Cell Commun Signal 16(1):60, 2018. e-Pub 2018. PMID: 30227871.
- Dhar SS, Zhao D, Lin T, Gu B, Pal K, Wu SJ, Alam H, Lv J, Yun K, Gopalakrishnan V, Flores ER, Northcott PA, Rajaram V, Li W, Shilatifard A, Sillitoe RV, Chen K, Lee MG. MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. Mol Cell 70(5):825-841.e6, 2018. e-Pub 2018. PMID: 29861161.
- Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K, Lulla RR, Goldman S, Nazarian J, Rajaram V, Fangusaro J, Gopalakrishnan V. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget 9(4):5233-5250, 2018. e-Pub 2018. PMID: 29435175.
- Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S, Gopalakrishnan V. Targeting P-selectin blocks neuroblastoma growth. Oncotarget 8(49):86657-86670, 2017. e-Pub 2017. PMID: 29156825.
- Dobson THW, Hatcher RJ, Swaminathan J, Das CM, Shaik S, Tao RH, Milite C, Castellano S, Taylor PH, Sbardella G, Gopalakrishnan V. Regulation of USP37 Expression by REST-Associated G9a-Dependent Histone Methylation. Mol Cancer Res 15(8):1073-1084, 2017. e-Pub 2017. PMID: 28483947.
- Somanchi SS, Kennis BA, Gopalakrishnan V, Lee DA, Bankson JA. In vivo (19)F-magnetic resonance imaging of adoptively transferred NK cells. Methods Mol Biol 1441:317-32, 2016. e-Pub 2016. PMID: 27177678.
- Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol 125(1):133-41, 2015. e-Pub 2015. PMID: 26255071.
- Das CM, Taylor P, Gireud M, Singh A, Lee D, Fuller G, Ji L, Fangusaro J, Rajaram V, Goldman S, Eberhart C, Gopalakrishnan V. The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. Oncogene 32(13):1691-701, 2013. e-Pub 2013. PMID: 33665064.
- Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski IB, MacDonald T, Hasselblatt M, Riedemann L, Laureano A, Cooper L, Gopalakrishnan V. REST Is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther 11(8):1713-23, 2012. e-Pub 2012. PMID: 22848092.
- Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, Stewart J, Zage P, Gopalakrishnan V. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells. Cancer 117(22):5189-202, 2011. e-Pub 2011. PMID: 21523764.
- Kong M, Zhang M, Gopalakrishnan V, Wolff J. Dose-Time-Effect modeling for cancer cell growth in In-vitro experiments. Stat Biopharm Res 2(1):84-96, 2010. e-Pub 2010.
- Schreck KC, Taylor HP, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, and Eberhart CG. The Notch target HES1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clin Cancer Res 16(24):6060-70, 2010. e-Pub 2010. PMID: 21169257.
- Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 46(15):2771-80, 2010. e-Pub 2010. PMID: 20886683.
- Gopalakrishnan V, Bie B, Kang ND, Grill R, Adams H, Pan ZZ, Majumder S. The cerebellar environment modulates REST-mediated conversion of myoblasts into glutamatergic neurons. Stem Cells 28(10):1839-1847, 2010. e-Pub 2010. PMID: 20799335.
- Prasad P, Vasquez H, Das CM, Gopalakrishnan V, Wolff JE. Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. J Neurooncol 91(3):279-86, 2009. e-Pub 2009. PMID: 18853233.
- Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, Hasselblatt M, Paulus W, Fuller G, Wolff JE, Gopalakrishnan V. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 93(3):303-18, 2009. e-Pub 2009. PMID: 19148581.
- Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C):2437-42, 2008. e-Pub 2008. PMID: 18751431.
- Zhang M, Aguilera D, Das C, Vasquez H, Zage P, Gopalakrishnan V, Wolff J. Measuring cytotoxicity: A new perspective on LC50. Anticancer Res 27(1A):35-8, 2007. e-Pub 2007. PMID: 17352213.
- Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85(2):159-70, 2007. e-Pub 2007. PMID: 17534580.
- X* S, V* G, Stearns D, Aldape K, Lang FF, Fuller G, Snyder E, Eberhart CG, (*Equal Contribution) MS. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Molecular Cell Biology 26:1666-78, 2006. e-Pub 2006. PMID: 16478988.
- Zhang M, Das C, Vasquez H, Aguilera D, Zage PE, Gopalakrishnan V, Wolff JE. Predicting tumor cell repopulation after response: mathematical modeling of cancer cell growth. Anticancer Research 26:2933-6, 2006. e-Pub 2006. PMID: 16886616.
- Watanabe Y, Kameoka S, Gopalakrishnan V, Aldape KD, Pan ZZ, Lang FF, (Equal Contribution) MS. Conversion of myoblasts to physiologically active neuronal phenotype. Genes & Development 18:889-900, 2004. e-Pub 2004. PMID: 15078815.
- Gopalakrishnan V, Simancek P, Houchens C, Snaith HA, Frattini MG, Sazer S, Kelly TJ. Redundant control of rereplication in fission yeast. Proceedings of the National Academy of Sciences U S A 98:13114-9, 2001. e-Pub 2001. PMID: 11606752.
- Khan SA, Sheikh S, Sheahan L, Van Horn G, Gopalakrishnan V, Sverdrup F. Expression of E1 protein of human papillomaviruses in eukaryotic cells. Methods Enzymol 306:328-36, 1999. e-Pub 1999. PMID: 10432463.
- Gopalakrishnan V, Sheahan L, Khan SA. DNA replication specificity and functional E2 interaction of the E1 proteins of human papillomavirus types 1a and 18 are determined by their carboxyl-terminal halves. Virology 256:330-9, 1999. e-Pub 1999. PMID: 10191198.
- Gopalakrishnan V, Walker S, Khan SA. Stimulation of human papillomavirus type 1a DNA replication by a multimerized AT-rich palindromic sequence. Virology 214(1):301-6, 1995. e-Pub 1995. PMID: 8525634.
- Gopalakrishnan V, Khan SA. E1 protein of human papillomavirus type 1a is sufficient for initiation of viral DNA replication. Proc Natl Acad Sci U S A 91(20):9597-601, 1994. e-Pub 1994. PMID: 7937813.
- Bravo-Algeria JB, Maegawa S, Scutti JB, Brugmann W, Lee DA, Cooper LJN, Goldman S, Gopalakrishnan V. MS-275 enhances sensitivity of DIPG cells to NK-mediated cytolysis by upregulating L1CAM expression.
- Zheng Y, Shi Y, Kleinerman ES, Singh A, Maegawa S, Cheng D, Guo L, Xie Y, Gorlick R, Daw N, Anjier A, Gopalakrishnan V, Gordon N. BRD4 regulates Gemcitabine efficacy by modulating autophagy activity in osteosarcoma cells.
- J* S, A* S, Taylor P, Fangusaro J, Rajaram V, Goldman S, Zweidler-McKay P, Hasselblatt M, Gopalakrishnan V. Feedback control of REST transcription in medulloblastoma.
- Dhar S, Gu B, Lin T, Chen K, Pal K, McArthur MJ, Gopalakrishnan V, Shilatifard A, Li W, Sillitoe R, Lee MG. MLL4 suppresses medulloblastoma by suppressing oncogenic pathways. (Molecular Cell-under revision).
- Singh A, Haltom A, Yang Y, Tao RH, Guo L, Lin X, Gopalakrishnan V. A novel USP37 mouse model reveals a role for the deubiquitylase in postnatal brain development.
- P* T, R* T, Stratton S, Maegawa S, Singh A, Gireud M, Goldman S, Fangusaro J, Rajaram V, Hasselblatt M, Barton MC, Goplakrishnan V. REST and HES1 co-occupy the p27 upstream regulatory region to coordinately regulate gene expression. (Nucleic Acids Research submitted, *equal contribution).
- Manickavinayahar S, Cheng D, Maegawa S, Swaminathan J, Singh A, Yang Y, Gordon N, Najjar A, Daw N, Zaky W, Gorlick R, Guo L, Xu L, Gopalakrishnan V. REST elevation is a therapeutic vulnerability in DIPG.
- RH* T, T* D, Shaik S, Taylor P, Kennis B, Qi L, Khatua S, X-N L, Goldman S, Lulla R, Fangusaro J, MacDonald T, Li XN, Hawkins C, Rajaram V, Gopalakrishnan V. A novel mouse model implicates histone H3 lysine 9 methylation in Ptch1 loss of heterozygosity and Akt hyperactivity in medulloblastoma. (Science Signaling-under revision *equal contribution).
- Cheng S, Maegawa S, Sharma A, Sridharan S, Harmanci A, Dobson T, Swaminathan J, Haltom A, Shaik S, Tarapore R, Harmanci A, Gordon N, Najjar A, Daw N, Zaky W, Gorlick R, Guo L, Xu L, Gopalakrishnan V. ONC201 enhances diffuse midline gliomas response to NK-cell immunotherapy.
- Callegari K, Dobson T, Bravo-Alegria JB, Shaik S, Maegawa S, Sharma A, Li XN, Gopalakrishnan V. REST controls CXCR4 signaling and cell migration during cerebellar development.
- Swaminathan J, Ho B, Maegawa S, Brugmann W, Bravo-Allegria JB, Khatua S, Laureano A, Silla L, Cooper LJN, Sandberg DI, Zaky W, Lee DA, Huang A, Gopalakrishnan V. Immuno-epigenomic analyses reveals a role for REST and CTCF in immunosuppression and escape of ATRTs from NK-mediated cytolysis.
- Tao RH, Brugmann W, Keith M, Somanchi S, Cooper L, Sandberg D, Khatua S, Zaky W, Moyes J, Schellingerhout D, Lee D, Bankson J, Gopalakrishnan V. Novel Imaging agent to track infused cells for brain tumor immunotheraphy.
- S* S, B* K, Fangusaro J, Lulla R, Rajaram V, Goldman S, Nazarian J, Gopalakrishan V. REST controls gremlin expression and DIPG vasculature. Oncotarget.
- Singh A, Lei G, Swaminathan J, Lin X, Gopalakrishnan V. REST-UBR5 interaction controls SOX2 degradation in SHH-driven medulloblastoma.
- Singh A, Haltom A, Cheng DH, Gopalakrishnan V. USP37 has context-specific tumor suppressive and oncogenic functions in medulloblastoma.
Invited Articles
- Gopalakrishnan V, Tao RH, Dobson T, Brugmann W, Khatua S. Medulloblastoma development: tumor biology informs treatment decisions. CNS Oncology 4(2):79-89, 2015. e-Pub 2015.
- Gopalakrishnan V. REST and the RESTless: in stem cells and beyond. Future Neurol 4(3):317-329, 2009. e-Pub 2009. PMID: 19885378.
- Zaky W, Manton C, Miller C, Khatua S, Gopalakrishnan V, Chandra C. The ubiquitin proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities. Cancer and metastasis reviews-special issue.
Review Articles
- Mahendran MIMS, Gopalakrishnan V, Saravanan V, Dhamodharan R, Jothimani P, Balasubramanian M, Singh AK, Vaithianathan R. Managing drug therapy-related problems and assessment of chronic diabetic wounds. Curr Med Res Opin 40(12):2077-2093, 2024. e-Pub 2024. PMID: 39402701.
- Saravanan V, Gopalakrishnan V, Mahendran MIMS, Vaithianathan R, Srinivasan S, Boopathy V, Krishnamurthy S. Biofilm mediated integrin activation and directing acceleration of colorectal cancer. APMIS 132(10):688-705, 2024. e-Pub 2024. PMID: 39246244.
- Marchant JK, Ferris NG, Grass D, Allen MS, Gopalakrishnan V, Olchanyi M, Sehgal D, Sheft M, Strom A, Bilgic B, Edlow B, Hillman EMC, Juttukonda MR, Lewis L, Nasr S, Nummenmaa A, Polimeni JR, Tootell RBH, Wald LL, Wang H, Yendiki A, Huang SY, Rosen BR, Gollub RL. Mesoscale Brain Mapping: Bridging Scales and Modalities in Neuroimaging - A Symposium Review. Neuroinformatics 22(4):679-706, 2024. e-Pub 2024. PMID: 39312131.
- Rav E, Maegawa S, Gopalakrishnan V, Gordon N. Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. J Immunol 211(7):1067-1072, 2023. e-Pub 2023. PMID: 37722095.
- Shi Y, Shen HM, Gopalakrishnan V, Gordon N. Epigenetic Regulation of Autophagy Beyond the Cytoplasm: A Review. Front Cell Dev Biol 9:675599, 2021. e-Pub 2021. PMID: 34195194.
- Haltom AR, Toll SA, Cheng D, Maegawa S, Gopalakrishnan V, Khatua S. Medulloblastoma epigenetics and the path to clinical innovation. J Neurooncol 150(1):35-46, 2020. e-Pub 2020. PMID: 32816225.
- Dobson THW, Gopalakrishnan V. Preclinical Models of Pediatric Brain Tumors-Forging Ahead. Bioengineering (Basel) 5(4), 2018. e-Pub 2018. PMID: 30279402.
Other Articles
- Singh A, Cheng DH, Haltom A, Yang Y, Dobson T, Hatcher R, Rajaram V, Gopalakrishnan V Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells, 2025.
- Nagori SA, Gopalakrishnan V, Rangarajan H, Kulkarni V, Roychoudhury A Does intra-articular injection of platelet-rich plasma/platelet-rich fibrin improve outcomes after temporomandibular joint arthrocentesis? A systematic review and meta-analysis. Br J Oral Maxillofac Surg 62(8):676-684, 2024. PMID: 39097521.
- Swaminathan J, Dobson T, Maegawa S, Haltom A, Hatcher R, Yang Y, Sharma A, Bravo-Allegria J, Rajaram V, Xu L, Gopalakrishnan V REST and CBX7 control USP37 transcription during neurogenesis of cerebellar granule progenitor cells.
Abstracts
- Gopalakrishnan V, Taylor P, Fangusaro J, Rajaram V, Goldman S. Targeting REST for Medulloblastoma Therapy. Abstract at the Society for Neuro-Oncology 16th Annual Scientific Meeting & Education Day in New Orleans, LA, 2011. e-Pub 2011.
- Singh A, Rokes C, Gireud M, Stewart J, Baumgartner J, Fletcher J, Zage PE, Gopalakrishnan V. REST and beta-TRCP in neuroblastoma. Abstracts of the 102nd American Association of Cancer Research Annual Meeting, Orlando, FL, 2011, 2011. e-Pub 2011.
- Rokes C, Zage PE, Gopalakrishnan V. Retinoic Acid Promotes Proteasomal Degradation of REST and Neuronal Differentiation in Neuroblastoma Cells. Abstract at the 23rd Annual Meeting of The American Society of Pediatric Hematology/Oncology, Montreal, Quebec, Canada, 2010. e-Pub 2010.
- Schreck KC, Taylor HP, Bar EE, Gopalakrishnan V, Giaino N, Eberhart C. Crosstalk between Notch and Hedgehog Signaling as a Mechanism of Escape from Pharmacological Notch Inhibition. Abstracts of the American Association of Cancer Research 101st Annual Meeting, 2010. e-Pub 2010.
- Das CM, Taylor P, Kommagani R, Su X, Aguilera DG, Wolff JE, Kadakia MP, Flores ER, Gopalakrishnan V. VPA upregulates p63 expression and sensitizes medulloblastoma cells to etoposide. Abstracts of the Society of Neuro-Oncology Scientific Meeting, Montreal, Canada, 2010. e-Pub 2010.
- Taylor P, Kang ND, Das C, Aguilera DG, Rajaram V, Goldman S, Fangusaro J, Gopalakrishnan V. Histone deacetylase inhibitors promote REST degradation and neuronal differentiation in medulloblastoma. Abstracts of the Society of Neuro-Oncology Scientific Meeting, Montreal, Canada, 2010. e-Pub 2010.
- Das C, Taylor P, Gopalakrishnan V. NRSF-mediated Regulation of p27/CDKNIB: Implications for Medulloblastoma Cell Proliferation. Abstracts of the American Association for Cancer Research Genetics and Biology of Brain Tumors Meeting, San Diego, CA, 2009. e-Pub 2009.
- Aguilera DG, Rajaram V, Fangusaro J, Tomita T, Gopalakrishnan V, Wen S, Goldman S. REST Expression and its Prognostic Relevance in Ependymomas. Abstract from the 2009 Joint Meeting of SNO and AANS/CNS Section on Tumors, New Orleans, LA, 2009. e-Pub 2009.
- Das C, Aguilera D, Kommagari R, Thomas A, Joyce C, Wolff J, Kadakia M, Gopalakrishnan V. Synergy Between HDAC Inhibitors and Etoposide in Medulloblastoma Cells: p53-dependent and Independent Mechanisms. Abstracts of the American Association for Cancer Research 99th Annual Meeting, San Diego, CA, 2008. e-Pub 2008.
- Aguilera D, Das CM, Wolff JEA, Zage PE, and Gopalakrishnan V. Valproic Acid Enhances Etoposide-Induced Cytotoxicity in Neuroblastoma Cells. Presented at the Advances in Neuroblastoma Research (ANR) Conference, Chiba, Japan, 2008. e-Pub 2008.
- Gopalakrishnan V, Anderson P, Das C, Aguilera D, Vasuez H, Prasad P, Zhang M, Wolff J. Valproic Acid Sensitizes High Grade Glioma Cells to Etoposide. Abstract of the SIOP Meetings, Mumbai, India, 2007. e-Pub 2007.
- Das C, Aguilera DG, Vasquez H, Zhang M, Prasad P, Wolff JE, Gopalakrishnan V. Valproic acid enhances cytotoxicity of etoposide in human glioblastoma cells. Abstracts of the AACR Meeting, Los Angeles, CA, 2007. e-Pub 2007.
- Masoudi A, Elopre M, Amini E, Nagel M, Ater J, Gopalakrishnan V, Wolff J. Valporic acid in the treatment of pediatric high grade glioma: Retrospective chart review. Abstracts of the Society of Neuro-oncology, Dallas, TX, 2007. e-Pub 2007.
- Majumder S, Gopalakrishnan V, et al XS. Abnormal expression of REST/NRSF and Myc in neurol stem/progenitor cells causes cerebellar tumors by blocking differentiation. Abstracts of the 14th European Cancer Conference, Barcelona, Spain, 2007. e-Pub 2007.
- Aguilera D, Zage P, Wolff J, Gopalakrishnan V. Effect of the HDAC inhibitor MS-275 on medulloblastoma growth and viability. Abstracts of the Society of Neuro-Oncology Annual Meeting, Orlando, FL, 2006. e-Pub 2006.
- Aguilera V, Wolff J, Gopalakrishnan V. Histone de-acetylase inhibitors in medulloblastoma therapy. Abstracts of the International Society of Pediatric Oncology, Geneva, Switzerland, 2006. e-Pub 2006.
- Aguilera V, Vasquez H, Das C, Wolff J, Gopalakrishnan V. Demethylating agents and histone de-acetylase inhibitors in medulloblastoma. Abstracts of the American Society for Clinical Oncology, San Francisco, CA, 2006. e-Pub 2006.
- Gopalakrishnan V. A novel therapeutic target for medulloblastomas. Abstracts of the Society of Neuro-Oncology Annual Meeting, Orlando, FL, 2006. e-Pub 2006.
- Aguilera V Vasquez H, Das C, Wolff J, Gopalakrishnan V. Epigenetic changes in medulloblastoma. Abstracts of the International Brain Tumor Meeting, Tokyo, Japan, 2006. e-Pub 2006.
- Gopalakrishnan V, Fuller G, Su X, Price R, Cohen Z, Lang F, Sawaya R, Majumder S. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron restrictive silencing factor, which can be functionally countered by REST-VP16. Abstracts of the University of California, San Francisco Pediatric Brain Tumor Meeting, Napa Valley, CA, 2006. e-Pub 2006.
- Das C, Zage P, Wolff J, Gopalakrishnan V. Study of valproic acid as a chemosensitizer in medulloblastoma therapy. Abstracts of the Society of Neuro-Oncology Annual Meeting, Orlando, FL, 2006. e-Pub 2006.
- Aguilera V, Vasquez H, Das C, Gopalakrishnan V, Wolff J. Demethylating agents and histone de-acetylase inhibitors in medulloblastoma. Abstracts of the 12th International Symposium on Pediatric Neuro-Oncology, Washington, DC, 2005. e-Pub 2005.
- Majumder S, Gopalakrishnan V, Su X, Kameoka S. REST/NRSF, a key player in medulloblastoma tumorigenesis. Abstracts of the Brain Tumor Society, Houston, TX, 2004. e-Pub 2004.
- Gopalakrishnan V, Simancek P, Houchens C, Snaith H A, Sazer S, Kelly TJ. Interaction of Cdt1 and Cdc18 in the control of S. pombe DNA replication. Abstracts of the DNA Replication Meeting, Cold Spring Harbor, NY, 2001. e-Pub 2001.
- Gopalakrishnan V, Simancek P, Houchens C, Kelly TJ. The role of fission yeast protein Cdt1 in the initiation of DNA replication. Abstracts of the Cell Cycle Meeting, Cold Spring Harbor, NY, 2000. e-Pub 2000.
Book Chapters
- Farras J, Gupta S, Gopalakrishnan V, Khatua S. NK cells in Brain Tumors. In: Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy, 2020.
- Swaminathan J, Gopalakrishnan V. Repurposing drugs for immunotherapy. In: From Immunology to immunotherapy. From Immunology to Immunotherapy, 2017.
- Kennis, Gopalakrishnan V. 19F Imaging to monitor successful local infusion of NK cells in the brain. In: Natural killer cells: Methods and protocols, 2015.
- Gopalakrishnan V, Aguilera D. Epigenetic Control of Apoptosis in Brain Tumors: Implications for Therapy. In: Cell Death and Cancer. Research SignPost, 2009.
Patient Reviews
CV information above last modified March 10, 2026